

Rubella (German Measles) (Infectious Disease) - Drugs in Development, 2021

<https://marketpublishers.com/r/R7844DBCBF8AEN.html>

Date: October 2021

Pages: 44

Price: US\$ 2,000.00 (Single User License)

ID: R7844DBCBF8AEN

Abstracts

Rubella (German Measles) (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rubella (German Measles) - Drugs In Development, 2021, provides an overview of the Rubella (German Measles) (Infectious Disease) pipeline landscape. Rubella also known as the German measles is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rubella (German Measles) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Rubella (German Measles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Rubella (German Measles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 2, 1, 3 and 2 respectively. Similarly, the Universities portfolio in Phase III stages comprises 2 molecules, respectively.

Rubella (German Measles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (German Measles) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Rubella (German Measles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Rubella (German Measles) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Rubella (German Measles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of

administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Rubella (German Measles) (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Rubella (German Measles) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Rubella (German Measles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Rubella (German Measles) - Overview
- Rubella (German Measles) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Rubella (German Measles) - Therapeutics Assessment
- Assessment by Route of Administration
- Assessment by Molecule Type
- Rubella (German Measles) - Companies Involved in Therapeutics Development
- Beijing Minhai Biotechnology Co Ltd
- Cadila Healthcare Ltd
- Daiichi Sankyo Co Ltd
- Enesi Pharma Ltd
- GlaxoSmithKline Plc
- Indian Immunologicals Ltd
- Micron Biomedical Inc
- Sinovac Biotech Ltd
- Univercells SA
- Vaxxas Inc
- Zhongyianke Biotech Co Ltd
- Rubella (German Measles) - Drug Profiles
- (measles + mumps + rubella + varicella) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (measles + mumps + rubella + varicella) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (measles + mumps + rubella) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress

(measles + mumps + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3])

vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BK-1601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rubella vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VN-0102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rubella (German Measles) - Dormant Projects

Rubella (German Measles) - Product Development Milestones

Featured News & Press Releases

Aug 02, 2021: GSK files for licensure of MMR vaccine in the US

May 05, 2021: Enesi Pharma achieves key milestone in development of thermostable solid-dose live vaccines against measles and rubella

Mar 18, 2020: Vaxxas awarded US\$5 million grant for clinical study of measles and rubella vaccination

Nov 30, 2019: Vaxxas was awarded research and development fund of USD 4,997,693 from Bill & Melinda Gates Foundation

Nov 30, 2016: Vaxxas was awarded research and development fund of USD 4,479,552 from Bill & Melinda Gates Foundation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Rubella (German Measles), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Rubella (German Measles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021
Rubella (German Measles) - Pipeline by Cadila Healthcare Ltd, 2021
Rubella (German Measles) - Pipeline by Daiichi Sankyo Co Ltd, 2021
Rubella (German Measles) - Pipeline by Enesi Pharma Ltd, 2021
Rubella (German Measles) - Pipeline by GlaxoSmithKline Plc, 2021
Rubella (German Measles) - Pipeline by Indian Immunologicals Ltd, 2021
Rubella (German Measles) - Pipeline by Micron Biomedical Inc, 2021
Rubella (German Measles) - Pipeline by Sinovac Biotech Ltd, 2021
Rubella (German Measles) - Pipeline by Univercells SA, 2021
Rubella (German Measles) - Pipeline by Vaxxas Inc, 2021
Rubella (German Measles) - Pipeline by Zhongyianke Biotech Co Ltd, 2021
Rubella (German Measles) - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Rubella (German Measles), 2021

Number of Products under Development by Companies, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Rubella (German Measles) (Infectious Disease) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/R7844DBCBF8AEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R7844DBCBF8AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970